Head-To-Head Survey: PROCEPT BioRobotics (NASDAQ:PRCT) versus Apyx Medical (NASDAQ:APYX)

Apyx Medical (NASDAQ:APYX) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Volatility & Risk

Apyx Medical has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.

Valuation and Earnings

This table compares Apyx Medical and PROCEPT BioRobotics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$52.35 million	1.05	-$18.71 million	($0.83)	-1.76
PROCEPT BioRobotics	$136.19 million	27.95	-$105.90 million	($1.95)	-37.41

Apyx Medical has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Apyx Medical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

55.3% of Apyx Medical shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 16.8% of Apyx Medical shares are owned by insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Apyx Medical and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-58.59%	-137.98%	-36.74%
PROCEPT BioRobotics	-50.07%	-38.57%	-26.06%

Analyst Ratings

This is a summary of recent ratings and price targets for Apyx Medical and PROCEPT BioRobotics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	0	2	0	1	2.67
PROCEPT BioRobotics	0	1	6	0	2.86

PROCEPT BioRobotics has a consensus target price of $97.86, suggesting a potential upside of 34.14%. Given PROCEPT BioRobotics’ stronger consensus rating and higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Apyx Medical.

Summary

PROCEPT BioRobotics beats Apyx Medical on 10 of the 15 factors compared between the two stocks.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.